aluates Reports

$ 0.0

Automative

Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-39N14041

Global Community Acquired Bacterial Pneumonia CABP Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Research Report 2025

Code: QYRE-Auto-39N14041

Report

May 2025

Pages:87

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Nabriva Therapeutics

Melinta Therapeutics

Forest Pharmaceuticals

Cumberland Pharmaceuticals Inc

Theravance Biopharma

Shionogi

Takeda

TiGenix NV

Wakunaga Pharmaceutical

Pfizer, Paratek Pharmaceuticals,

Merck Sharp & Dohme Inc.

Cubist Pharmaceuticals LLC

Allergan, Eagle Pharmaceutical Inc.

Combioxin SA

Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size

Therapeutics was valued at US$ 5239 million in the year 2024 and is projected to reach a revised size of US$ 7482 million by 2031, growing at a CAGR of 5.3% during the forecast period.

Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market

The global market for Community Acquired Bacterial Pneumonia(CABP)

Community Acquired Bacterial Pneumonia(CABP) Therapeutics includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Community Acquired Bacterial Pneumonia(CABP) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community Acquired Bacterial Pneumonia(CABP) Therapeutics.

The Community Acquired Bacterial Pneumonia(CABP) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Community Acquired Bacterial Pneumonia(CABP) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Community Acquired Bacterial Pneumonia(CABP) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Report

Report Metric	Details
Report Name	Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market
Accounted market size in year	US$ 5239 million
Forecasted market size in 2031	US$ 7482 million
CAGR	5.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Pleuromutilin Cephalosporin Glycylcycline Oxazolidinone Ketolide
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals,, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community Acquired Bacterial Pneumonia(CABP) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market growing?

Ans: The Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market size in 2031?

Ans: The Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market size in 2031 will be US$ 7482 million.

Who are the main players in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market report?

Ans: The main players in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market are Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals,, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix

What are the Application segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market report?

Ans: The Applications covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market report?

Ans: The Types covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market report are Pleuromutilin, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide

Recommended Reports

Respiratory Diseases

Lung Cancer Therapy

Infection & Antibiotics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Pleuromutilin

1.2.3 Cephalosporin

1.2.4 Glycylcycline

1.2.5 Oxazolidinone

1.2.6 Ketolide

1.3 Market by Application

1.3.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Perspective (2020-2031)

2.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Growth Trends by Region

2.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Dynamics

2.3.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Industry Trends

2.3.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers

2.3.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges

2.3.4 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Revenue

3.1.1 Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue

3.4 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Concentration Ratio

3.4.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2024

3.5 Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics Head office and Area Served

3.6 Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics, Product and Application

3.7 Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Breakdown Data by Type

4.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Type (2026-2031)

5 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Breakdown Data by Application

5.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2020-2031)

6.2 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025)

6.4 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2020-2031)

7.2 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025)

7.4 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2020-2031)

9.2 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Nabriva Therapeutics

11.1.1 Nabriva Therapeutics Company Details

11.1.2 Nabriva Therapeutics Business Overview

11.1.3 Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.1.4 Nabriva Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.1.5 Nabriva Therapeutics Recent Development

11.2 Melinta Therapeutics

11.2.1 Melinta Therapeutics Company Details

11.2.2 Melinta Therapeutics Business Overview

11.2.3 Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.2.4 Melinta Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.2.5 Melinta Therapeutics Recent Development

11.3 Wakunaga Pharmaceutical

11.3.1 Wakunaga Pharmaceutical Company Details

11.3.2 Wakunaga Pharmaceutical Business Overview

11.3.3 Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.3.4 Wakunaga Pharmaceutical Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.3.5 Wakunaga Pharmaceutical Recent Development

11.4 Forest Pharmaceuticals

11.4.1 Forest Pharmaceuticals Company Details

11.4.2 Forest Pharmaceuticals Business Overview

11.4.3 Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.4.4 Forest Pharmaceuticals Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.4.5 Forest Pharmaceuticals Recent Development

11.5 Pfizer, Paratek Pharmaceuticals,

11.5.1 Pfizer, Paratek Pharmaceuticals, Company Details

11.5.2 Pfizer, Paratek Pharmaceuticals, Business Overview

11.5.3 Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.5.4 Pfizer, Paratek Pharmaceuticals, Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.5.5 Pfizer, Paratek Pharmaceuticals, Recent Development

11.6 Cumberland Pharmaceuticals Inc.

11.6.1 Cumberland Pharmaceuticals Inc. Company Details

11.6.2 Cumberland Pharmaceuticals Inc. Business Overview

11.6.3 Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.6.4 Cumberland Pharmaceuticals Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.6.5 Cumberland Pharmaceuticals Inc. Recent Development

11.7 Theravance Biopharma

11.7.1 Theravance Biopharma Company Details

11.7.2 Theravance Biopharma Business Overview

11.7.3 Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.7.4 Theravance Biopharma Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.7.5 Theravance Biopharma Recent Development

11.8 Merck Sharp & Dohme Inc.

11.8.1 Merck Sharp & Dohme Inc. Company Details

11.8.2 Merck Sharp & Dohme Inc. Business Overview

11.8.3 Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.8.4 Merck Sharp & Dohme Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.8.5 Merck Sharp & Dohme Inc. Recent Development

11.9 Cubist Pharmaceuticals LLC

11.9.1 Cubist Pharmaceuticals LLC Company Details

11.9.2 Cubist Pharmaceuticals LLC Business Overview

11.9.3 Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.9.4 Cubist Pharmaceuticals LLC Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.9.5 Cubist Pharmaceuticals LLC Recent Development

11.10 Shionogi Inc.

11.10.1 Shionogi Inc. Company Details

11.10.2 Shionogi Inc. Business Overview

11.10.3 Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.10.4 Shionogi Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.10.5 Shionogi Inc. Recent Development

11.11 Allergan, Eagle Pharmaceutical Inc.

11.11.1 Allergan, Eagle Pharmaceutical Inc. Company Details

11.11.2 Allergan, Eagle Pharmaceutical Inc. Business Overview

11.11.3 Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.11.4 Allergan, Eagle Pharmaceutical Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.11.5 Allergan, Eagle Pharmaceutical Inc. Recent Development

11.12 Combioxin SA

11.12.1 Combioxin SA Company Details

11.12.2 Combioxin SA Business Overview

11.12.3 Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.12.4 Combioxin SA Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.12.5 Combioxin SA Recent Development

11.13 Takeda

11.13.1 Takeda Company Details

11.13.2 Takeda Business Overview

11.13.3 Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.13.4 Takeda Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.13.5 Takeda Recent Development

11.14 TiGenix

11.14.1 TiGenix Company Details

11.14.2 TiGenix Business Overview

11.14.3 TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction

11.14.4 TiGenix Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

11.14.5 TiGenix Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Nabriva Therapeutics

Melinta Therapeutics

Forest Pharmaceuticals

Cumberland Pharmaceuticals Inc

Theravance Biopharma

Shionogi

Takeda

TiGenix NV

Wakunaga Pharmaceutical

Pfizer, Paratek Pharmaceuticals,

Merck Sharp & Dohme Inc.

Cubist Pharmaceuticals LLC

Allergan, Eagle Pharmaceutical Inc.

Combioxin SA

List of Tables

Table 1. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Pleuromutilin

Table 3. Key Players of Cephalosporin

Table 4. Key Players of Glycylcycline

Table 5. Key Players of Oxazolidinone

Table 6. Key Players of Ketolide

Table 7. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2020-2025)

Table 11. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2026-2031)

Table 13. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Trends

Table 14. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers

Table 15. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges

Table 16. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints

Table 17. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2024)

Table 20. Ranking of Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics, Product and Application

Table 24. Global Key Players of Community Acquired Bacterial Pneumonia(CABP) Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Application (2020-2025)

Table 32. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Application (2026-2031)

Table 34. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. Nabriva Therapeutics Company Details

Table 50. Nabriva Therapeutics Business Overview

Table 51. Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 52. Nabriva Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 53. Nabriva Therapeutics Recent Development

Table 54. Melinta Therapeutics Company Details

Table 55. Melinta Therapeutics Business Overview

Table 56. Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 57. Melinta Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 58. Melinta Therapeutics Recent Development

Table 59. Wakunaga Pharmaceutical Company Details

Table 60. Wakunaga Pharmaceutical Business Overview

Table 61. Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 62. Wakunaga Pharmaceutical Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Wakunaga Pharmaceutical Recent Development

Table 64. Forest Pharmaceuticals Company Details

Table 65. Forest Pharmaceuticals Business Overview

Table 66. Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 67. Forest Pharmaceuticals Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Forest Pharmaceuticals Recent Development

Table 69. Pfizer, Paratek Pharmaceuticals, Company Details

Table 70. Pfizer, Paratek Pharmaceuticals, Business Overview

Table 71. Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 72. Pfizer, Paratek Pharmaceuticals, Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 73. Pfizer, Paratek Pharmaceuticals, Recent Development

Table 74. Cumberland Pharmaceuticals Inc. Company Details

Table 75. Cumberland Pharmaceuticals Inc. Business Overview

Table 76. Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 77. Cumberland Pharmaceuticals Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 78. Cumberland Pharmaceuticals Inc. Recent Development

Table 79. Theravance Biopharma Company Details

Table 80. Theravance Biopharma Business Overview

Table 81. Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 82. Theravance Biopharma Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 83. Theravance Biopharma Recent Development

Table 84. Merck Sharp & Dohme Inc. Company Details

Table 85. Merck Sharp & Dohme Inc. Business Overview

Table 86. Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 87. Merck Sharp & Dohme Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 88. Merck Sharp & Dohme Inc. Recent Development

Table 89. Cubist Pharmaceuticals LLC Company Details

Table 90. Cubist Pharmaceuticals LLC Business Overview

Table 91. Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 92. Cubist Pharmaceuticals LLC Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 93. Cubist Pharmaceuticals LLC Recent Development

Table 94. Shionogi Inc. Company Details

Table 95. Shionogi Inc. Business Overview

Table 96. Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 97. Shionogi Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 98. Shionogi Inc. Recent Development

Table 99. Allergan, Eagle Pharmaceutical Inc. Company Details

Table 100. Allergan, Eagle Pharmaceutical Inc. Business Overview

Table 101. Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 102. Allergan, Eagle Pharmaceutical Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 103. Allergan, Eagle Pharmaceutical Inc. Recent Development

Table 104. Combioxin SA Company Details

Table 105. Combioxin SA Business Overview

Table 106. Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 107. Combioxin SA Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 108. Combioxin SA Recent Development

Table 109. Takeda Company Details

Table 110. Takeda Business Overview

Table 111. Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 112. Takeda Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 113. Takeda Recent Development

Table 114. TiGenix Company Details

Table 115. TiGenix Business Overview

Table 116. TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product

Table 117. TiGenix Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025) & (US$ Million)

Table 118. TiGenix Recent Development

Table 119. Research Programs/Design for This Report

Table 120. Key Data Information from Secondary Sources

Table 121. Key Data Information from Primary Sources

Table 122. Authors List of This Report

List of Figures

Figure 1. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Picture

Figure 2. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Pleuromutilin Features

Figure 5. Cephalosporin Features

Figure 6. Glycylcycline Features

Figure 7. Oxazolidinone Features

Figure 8. Ketolide Features

Figure 9. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Application: 2024 VS 2031

Figure 11. Hospital Pharmacy Case Studies

Figure 12. Retail Pharmacy Case Studies

Figure 13. Online Pharmacy Case Studies

Figure 14. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Report Years Considered

Figure 15. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region: 2024 VS 2031

Figure 18. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Players in 2024

Figure 19. Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2024

Figure 21. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2020-2031)

Figure 23. United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2020-2031)

Figure 27. Germany Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2020-2031)

Figure 35. China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2020-2031)

Figure 43. Mexico Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2020-2031)

Figure 47. Turkey Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Nabriva Therapeutics Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 51. Melinta Therapeutics Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 52. Wakunaga Pharmaceutical Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 53. Forest Pharmaceuticals Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 54. Pfizer, Paratek Pharmaceuticals, Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 55. Cumberland Pharmaceuticals Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 56. Theravance Biopharma Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 57. Merck Sharp & Dohme Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 58. Cubist Pharmaceuticals LLC Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 59. Shionogi Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 60. Allergan, Eagle Pharmaceutical Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 61. Combioxin SA Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 62. Takeda Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 63. TiGenix Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Cefaclor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pneumonia Therapeutics Market Research Report 2024

Chloangiocarcinoma CCA Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Viral Pneumonia Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Klebsiella Pneumoniae Infection Drug Market Research Report 2024

Pneumococcal Conjugate Vaccine PCV Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pneumonia Vaccine Market Insights Forecast to 2030

Multidrug Resistant Bacteria Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hospital Acquired Infections Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Carbapenem API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Systemic Fluoroquinolones Market Research Report 2025

Global Ceftazidime Market Insights Forecast to 2030

Global Clostridium Difficile Infection Treatment Market Research Report 2024

Pharmaceutical Grade Cabazitaxel Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ventilator Associated Pneumonia VAP Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Carbapenem Based Antibiotics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

ICU acquired Acute Kidney Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Amoxicillin Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions